Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 251

Results For "IMI"

4535 News Found

Honeywell, Recipharm to speed development of inhalers
News | August 18, 2023

Honeywell, Recipharm to speed development of inhalers

Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs


BASF, Promega and Swiss TPH collaborate to drive research for malaria control
News | August 18, 2023

BASF, Promega and Swiss TPH collaborate to drive research for malaria control

Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control


Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries
News | August 17, 2023

Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries

Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon


Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients
News | August 17, 2023

Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients

Jeet will be a trusted partner in cardiovascular care


Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US
News | August 17, 2023

Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US

Lupin actively contributes to alleviating the burden of COPD for patients across the nation


SSI Strategy to acquires NDA Group partner to form global life sciences consultancy
News | August 16, 2023

SSI Strategy to acquires NDA Group partner to form global life sciences consultancy

Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base


Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
Drug Approval | August 16, 2023

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.


Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP
Drug Approval | August 16, 2023

Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP

Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).


Mobile addicted generation heading towards hearing disorders: Survey
News | August 16, 2023

Mobile addicted generation heading towards hearing disorders: Survey

The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group